Impax Lab Settles Litigation Regarding OxyContin - Quick Facts

(RTTNews) - Impax Laboratories, Inc. (IPXL) announced it has entered into an agreement with Purdue Pharma L.P. to settle all outstanding patent litigation related to Impax's generic version of the currently marketed, reformulated OxyContin. Under the terms of the agreement, Impax will have the right to market a specified number of bottles of its generic OxyContin, contingent upon the company receiving final approval from the U.S. FDA on its ANDA for generic OxyContin, or to launch a specified number of bottles of an authorized generic version of OxyContin if Impax does not have final ANDA approval, in each case beginning January 1, 2016.

OxyContin is indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.